Companies Dominating the Pulmonary Drug Delivery Systems Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Lupin Limited
- Briggs Healthcare, Inc.
- Boehringer Ingelheim International GmbH
- Koninklijke Philips N.V.
- Merck & Co., Inc.
- 3M Company
- AstraZeneca PLC
- GSK plc
- GF Health Products, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of pulmonary drug delivery systems is estimated at USD 63.53 billion.
The global pulmonary drug delivery systems market is anticipated to grow from USD 60.56 billion in 2024 to USD 145.94 billion by 2037, exhibiting a CAGR of around 7% during the forecast period, between 2025 and 2037.
North America industry is anticipated to account for largest revenue share by 2037, due to increasing prevalence of lung diseases such as COPD, chronic bronchitis, and asthma in the region.
The major players in the market include Novartis AG, Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc.
